



Elpiscience to Participate in Cross-Pacific Collaboration Panel at BIO CEO & Investor Conference

Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, today announced that its co-founder and chief executive officer, Dr. Darren Ji, will participate in a panel discussion about R&D and innovation leading cross-pacific collaboration. The conference takes place at the Marriott Marquis in New York City from February 14 to 15 and virtually through February 17, 2022.

The panel, titled "What is New in Cross-Pacific Deal Making and Investment", will take place from 9:00 a.m. to 9:45 a.m. EST Wednesday, February 16, 2022, and will be accessible live to conference registrants.

A recorded Elpiscience presentation will also be available to registered attendees through the event platform beginning February 11.

For additional information, visit [BIO CEO & Investor Conference](#).

About Elpiscience:

Elpiscience is a clinical stage biopharmaceutical company focused on innovating and developing next-generation immunotherapy. The company has a robust pipeline of globally innovative molecules, covering wide range of targets in immuno-oncology. It has four molecules in clinical trials, including ES104, ES101, ES102, and ES002. Founded and managed by a team of biopharma industry leaders and scientists, Elpiscience is backed by renowned



investors including, Lilly Asia Ventures, Hillhouse Capital, Hyfinity Investments, Greater Bay Area Homeland Development Fund, CDH, DYEE Capital and Cormorant Asset Management.

Elpiscience endeavors to advance at least one innovative molecule into the clinic each year to benefit cancer patients worldwide.

Learn more at elpiscience.com

Investor inquiries:

John Craighead, Ph.D.
IR@elpiscience.com

Media inquiries:

Candy Zhao
PR@elpiscience.com